Surrozen (SRZN) Profit After Tax (2020 - 2026)
Surrozen (SRZN) posted quarterly Profit After Tax of -$127.5 million for Q1 2026, down 372.77% year-over-year from $46.7 million in Q1 2025, and up 30.38% quarter-over-quarter from -$183.1 million in Q4 2025.
Surrozen (SRZN) Profit After Tax (2020 - 2026) Analysis & Trends
Surrozen's Profit After Tax history runs 7 years deep, the most recent figure standing at -$127.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 372.77% year-over-year to -$127.5 million; the TTM figure through Mar 2026 stood at -$342.5 million (down 318.9% YoY), while the FY2025 annual figure was -$242.0 million, down 280.5% from the prior year.
- Profit After Tax for Q1 2026 stood at -$127.5 million, up from -$183.1 million in the prior quarter.
- The five-year high for Profit After Tax was $39.7 million in Q2 2025, with the low at -$183.1 million in Q4 2025.
- The 5-year median for Profit After Tax is -$13.4 million (2022), against an average of -$30.1 million.
- Peak annual rise in Profit After Tax reached 256.92% in 2025, while the deepest fall reached 5014.29% in 2025.
- Surrozen's Profit After Tax stood at -$470000.0 in 2022, then sank by 1796.38% to -$8.9 million in 2023, then plunged by 215.27% to -$28.1 million in 2024, then tumbled by 551.72% to -$183.1 million in 2025, then soared by 30.38% to -$127.5 million in 2026.
- Business Quant data shows SRZN's Profit After Tax at -$127.5 million in Q1 2026, -$183.1 million in Q4 2025, and -$71.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 50.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.20 Mn |
| Mar 31, 2026 | -127.51 Mn |
| Dec 31, 2025 | -183.13 Mn |
| Sep 30, 2025 | -71.60 Mn |
| Jun 30, 2025 | 39.70 Mn |
| Mar 31, 2025 | -26.97 Mn |
| Dec 31, 2024 | -28.10 Mn |
| Sep 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -25.30 Mn |
| Mar 31, 2024 | -8.83 Mn |
| Dec 31, 2023 | -8.91 Mn |
| Sep 30, 2023 | -10.45 Mn |
| Jun 30, 2023 | -9.40 Mn |
| Mar 31, 2023 | -14.30 Mn |
| Dec 31, 2022 | -470,000.00 |
| Sep 30, 2022 | -13.40 Mn |
| Jun 30, 2022 | -13.93 Mn |
| Mar 31, 2022 | -8.26 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | -14.02 Mn |